Photo from Yelak Biru/X
Jul 3, 2024, 06:28
Yelak Biru: Is myeloma science and clinical progress fast or slow?
Yelak Biru, President and CEO at the International Myeloma Foundation, shared on X:
“Is myeloma science and clinical progress fast or slow? Or just intentional?
- 2003/2006 – The 1st Bortezomib and Lenalidomide received FDA approval (L1 and L2)
- 2015 – SWOG S0777 published RVd as SOC for NDMM (L3)
- 2024 – 4 drug combo may become SOC for NDMM (non-frail) (L4)”
Source: Yelak Biru/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 15:06
Feb 21, 2025, 14:27
Feb 21, 2025, 14:13
Feb 21, 2025, 13:29